Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Revance Therapeutics announces positive results from RT002 phase 1/2 study in glabellar frown lines


Monday, 21 Apr 2014 04:55pm EDT 

Revance Therapeutics Inc:Announces positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines.RT002 is Revance's proprietary, injectable botulinum toxin investigational product that incorporates the patented TransMTS┬« technology and is designed to provide a longer lasting duration of effect.Says in the study, RT002 met its primary efficacy and safety endpoints.Says the open-label, dose escalating, Phase 1/2 study enrolled 48 adults in four cohorts.